Evaluation of Injection Techniques in Celiac Plexus Neurolysis
Evaluation of Injection Techniques in Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis (EUS-CPN)
1. To evaluate the efficacy of EUS-CPN in subjects who experience a sympathetic response during injection when compared with subjects who do not experience sympathetic response during injection.
EUS-CPN when performed in subjects who experience a sympathetic response during injection will have better pain relief when compared to subjects who do not experience a sympathetic response during injection.
調査の概要
詳細な説明
All adult patients with radiologically consistent pancreatic carcinoma referred to Florida Hospital to undergo EUS for staging and diagnostic FNA of pancreatic mass lesions will be eligible for study entry.
A history and physical examination will be performed to determine the character and quality of the pain and to evaluate for any contraindication for which EUS cannot be performed.
Written informed consent for study participation will be obtained at the same time as the consent for the procedure as this study is comparing standard of care treatment options in a regular treatment setting. Then, after giving written informed consents and prior to the index procedure, all patients will complete the following written assessments:
- Standardized 11-point continuous visual analog pain scale (12)
- Quality of life instruments: Functional Assessment of Cancer Therapy, Pancreatic Cancer (FACT-PA) (i.e. QLQ-30 and PAN-26) (13)
- Pain medication usage over prior 2 days (converted to equianalgesic doses of morphine)
- EUS will be performed in standard fashion by one of three experienced endoscopists
Eligible patients will be included if pancreatic carcinoma is confirmed by FNA performed during EUS and if EUS or CT staging shows unresectability of the tumor. Cytology evaluation of FNA is routinely provided during procedure by pathologist into the endoscopy room at our institution.
During EUS, included patients will receive CPN in the standard fashion. Whether a sympathetic response occurs or not during CPN, this will be documented. Sympathetic response will be defined as change in heart rate by >10 bpm and change in BP <10mmHg. The technique of EUS-CPN is as follows:
- Using a curvilinear array echoendosocpe, the region of the celiac plexus is visualized from the lesser curvature of the stomach by following the aorta to the origin of the main celiac artery. It is traced, by using counter-clockwise rotation, to its bifurcation into splenic and hepatic arteries, with Doppler US control if needed.
- CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin.
- A 20-gauge fenestrated CPN needle is used, its tip is placed slightly anterior and cephalic to the origin of the celiac artery.
- Aspiration is first performed to ensure that vascular puncture has not occurred.
- Bupivacaine is injected first, followed by alcohol.
- Patients will be observed for 2 to 4 hours, with careful monitoring of pulse, blood pressure and temperature.
- Following EUS, patients will be discharged and called at home by research nurse at 24 hours for evidence of pancreatitis or other complications from the procedure, Clinical research nurse* will also contact the patient at 1, 2, 4 weeks after EUS and then monthly until death or 1 year. Clinical research nurse* will be blinded to the documentation about sympathetic response. Assessment of pain scale, QOL, medication use and side effects will be performed.
- Following CPN, EUS operator will not be actively involved in patient care.
- Medical decisions for each patient will be made by the patient's primary physician and oncologist.
- Patient can be referred for rescue CPN if the patient's primary physician and oncologist feel that this is warranted.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Florida
-
Orlando、Florida、アメリカ、32803
- Florida Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Abdominal pain typical for pancreatic cancer ( pain score ≥ 3/10)
- Abdominal CT consistent with diagnosis of pancreatic cancer
- Pancreatic cancer confirmed by EUS-FNA
- Inoperable pancreatic cancer as determined during EUS or prior CT
Exclusion Criteria:
- Age under 19 years
- Unable to safely undergo EUS for any reason
- Coagulopathy (Prothrombin time > 18 secs, platelet count < 80,000/ml)
- Previous CPN or other neurolytic block that could affect pancreatic cancer-related pain or had implanted epidural or intrathecal analgesic therapy
- Another cause for abdominal pain such as pseudocyst, ulcer or other intrabdominal disorder
- Noncompliance such that the patient would not return for subsequent follow-up
- Active alcohol or other drug use or significant psychiatric illness
- Unable to consent
- Non-English speaking
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
他の:sympathetic response
This group will be composed of subjects who experience a heart rate and/or Blood Pressure change during injection.
|
Sympathetic response will be defined as change in heart rate by >10 bpm and change in BP <10mmHg.
|
他の:no sympathetic response
This group will be made up of subjects that do not experience a vital sign change with injection for CPN.
|
no Sympathetic response will be defined as change in heart rate by <10 bpm and change in BP <10mmHg.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
abdominal pain
時間枠:within the first year post CPN
|
The primary endpoint of the study is abdominal pain. It will be assessed with a standardized 11-point continuous visual analog pain scale with "0" equaling no pain, "5" moderate pain and "10" worst pain ever. Before the procedure, patient will be instructed in the use of the pain scale by the research nurse. After the procedure, pain scores will be assessed by the clinical research nurse at the predetermined intervals. A complete response will be defined as an absence of abdominal pain requiring no pain medications. A partial response will be defined as a greater than 50% reduction in abdominal pain as assessed by the numerical 0-10 pain score. Failure will be defined as a reduction of ≤20% in pain score. |
within the first year post CPN
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 456550
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
痛みの臨床試験
-
Dexa Medica Group完了
Sympathetic responseの臨床試験
-
Vanderbilt University Medical Center完了
-
Foundation for Innovative New Diagnostics, SwitzerlandMinistry of Health, Malaysia; Hospital Sultanah Bahiyah; Malaysian AIDS Council募集